Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.

Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.

Abstract: Provided is a production method of glycolic acid having a first step of preparing glycolonitrile from formaldehyde and hydrocyanic acid and a second step of hydrolyzing the glycolonitrile into glycolic acid directly or via a glycolate salt, which method can produce glycolic acid in easy production and purification steps while consuming less energy. In the production method, by carrying out the first and second steps continuously or by storing the glycolonitrile obtained in the first step at pH 4 or less and carrying out a hydrolysis reaction of the second step at from pH 5 to 9, a production yield of glycolic acid, activity for the production of glycolic acid and accumulated concentration of glycolic acid are improved, resulting in the production of glycolic acid having an improved purity and quality.

Abstract: High yields and purity are obtained in the purification of enantiomers of chiral carboxylic acids by preparative-scale chromatography by including a tertiary alcohol in the mobile phase in conjunction with an acidic modifier and a hydrophobic solvent. The tertiary alcohol is superior to other, more commonly used alcohols by reducing the extent of esterification of the enantiomer that otherwise lowers the yield and the purity.

Abstract: The invention relates to an improved method for releasing an organic acid, preferably a carbon, sulfone or phosphone acid, particularly an alpha or beta hydroxycarbon acid, from the ammonia salt thereof by releasing and removing ammoniac and simultaneous extraction of the released acid, having an amine as a suitable extraction means from the aqueous phase. This method corresponds to a reactive extraction. The reactive extraction of an organic acid from the aqueous ammonia salt solution thereof can be significantly improved by the use of a strip medium or carrier gas, such as nitrogen, air, water vapor or inert gases such as argon. The released ammoniac is removed from the aqueous solution by the continuous gas flow and can be resupplied into a production process. The free acid can be obtained by a method such as distillation, rectification, crystallization, reextraction, chromatography, adsorption or by a membrane method from the extraction means.

Abstract: The present invention relates to an ionic liquid comprising an anion and a cation, wherein the cation is a primary, secondary or tertiary ammonium ion containing a protonated nitrogen atom.

Abstract: A process for purification of a hydroxycarboxylic acid by distillation, comprising: distilling a hydroxycarboxylic acid solution containing a high-boiling point hydroxy compound comprising at least one species selected from the group consisting of alcohols and phenols having a higher boiling point than the hydroxycarboxylic acid. As a result, a hydroxycarboxylic acid suitable as a starting material for production of a polyhydroxycarboxylic acid can be obtained. The purified hydroxycarboxylic acid is further polycondensed to provide a hydroxycarboxylic acid oligomer, which is de-polymerized to provide a cyclic ester comprising a dimer of the hydroxycarboxylic acid, and the cyclic ester is converted into a polyhydroxycarboxylic acid by ring-opening polymerization thereof.

Abstract: The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) a phosphonium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C. The precursor formulation comprises (1) at least 25 percent by weight of polyol, based on the weight of the precursor formulation; (2) less than 15 percent by weight of a trimerisation catalyst system, based on the weight of the precursor formulation, comprising; (a) a phosphonium cation; and (c) an isocyanate-timer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C.

Abstract: The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) a phosphatrane cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 C.

Abstract: Esters of tocotrienols having pharmacological activities pertinent to the treatment of breast cancer and other forms of cancer are disclosed herein. Among those compounds is (Z)-4-oxo-4-((R)-2,5,7,8-tetramethyl-2-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)chroman-6-yloxy)but-2-enoic acid. Tocotrienol esters were used to inhibit the growth and migration of +SA mammary epithelial cells and highly metastatic human breast cancer MDA-MB-231 cells respectively.

Abstract: Compounds and related methods as can be used for selective mevalonate pathway inhibitors.

Abstract: The present invention provides a microorganism useful for biologically producing 3-hydroxypropionic acid from a fermentable carbon source. Further, the microorganism comprises disruptions in specified genes and alterations in the expression levels of specified genes that are useful in a higher yielding process to produce 3-hydroxypropionic acid, compositions comprising renewably sourced 3-hydroxypropionic acid provided by said microorganism, and industrial relevant products made using such renewably sourced 3-hydroxypropionic acid.

Abstract: A compound of formula (I) for use as an adjuvant in vaccination; wherein R is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 50 carbon atoms; R1 is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 40 carbon atoms; each of R2, R3 and R4 is independently selected from an optionally-substituted alkylene, alkenylene, alkynylene, arylene, arylalkylene or alkylarylene moiety having from 1 to 40 carbon atoms; each of X, Y and Z is independently selected from an optionally-substituted alkylene, alkenylene, alkynylene, arylene, alkylarylene or cycloalkylene, ketone, ester, amide, imide, imine, thioether, ether, thioester, thioketone; and P is selected from hydrogen, an alkyl group, a sugar residue, or a metal, phosphonium or ammonium species; wherein at least one of X, Y and Z includes a moiety selected from cyclopropyl, C=A, C-AH and C—OR5; wherein R5 is alkyl or haloalkyl, and A is S, O or NR6, wherein R6

Abstract: The invention relates to use of a diacetylene compound as a colour former wherein the diacetylene compound has one of general formulae (I) to (V). The invention also includes methods of imparting colour to a material including a compound as defined above, which comprises subjecting the material to irradiation.

Abstract: The present invention relates to methods, systems and compositions, including genetically modified microorganisms, e.g., recombinant microorganisms, adapted to utilize one or more synthesis gas components in a microbial bio-production of one or more desired biomolecules and products of commercial interest.

Abstract: The present invention relates to a process for preparing hydroxycarboxylic acids, preferably ?- and ?-hydroxycarboxylic acids, from ammonium carboxylates of the general formula in which R1, R2 and R3 are each independently H, OH, (C1-C6)-alkyl optionally substituted by a hydroxyl group, (C1-C6)-alkenyl optionally substituted by a hydroxyl group, (C1-C6)-alkoxy optionally substituted by a hydroxyl group, (C1-C6) -alkylthio-(C1-C6)-alkyl optionally substituted by a hydroxyl group, (C6-C10)-aryl optionally substituted by a hydroxyl group, (C7-C12)-aralkyl optionally substituted by a hydroxyl group, (C3-C5)-heteroaryl optionally substituted by a hydroxyl group, with the proviso that at least one hydroxyl group is present in at least one R1, R2 and R3 radical, preferably R1?H, CH3, CH2CH3, C6H5, (CH2)2SCH3 and R2?H, CH3 and R3?OH, equally preferably R1?CH2OH, CHOHCH3 and R2?R3?H, CH3, more preferably R1?R2?CH3 and R3?OH, equally more preferably R1?CH2OH, R2?CH3 and R3?H, comprising the following step: heatin

Abstract: Amphiphilic derivatives composed of at least one fatty acid chain are derived from natural vegetable oils such as vernonia oil, lesquerella oil and castor oil, in which the several reactive groups such as epoxy, hydroxy and double bonds can be modified to polar and ionic groups. The head group of the amphiphilic derivative may be in the main fatty acid chain or in a side chain. The amphiphiles are useful for the formation of vesicles and micelles and for use as complexants and surfactants.

Abstract: A method is described for providing acute symptomatic relief to a subject with Parkinson's Disease (PD) or other CNS disorders resulting from dopamine deficiency in the brain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide therapeutic benefit in such neurological disorders. Preferred materials produce a ketosis is such that the total concentration of acetoacetate and (R)-3-hydroxybutyrate in the blood of the subject is raised to between 0.1 and 30 mM.

Abstract: Disclosed are novel oxylipins that are derived from ?-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. Also disclosed are The invention novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of SDA- and/or GLA-derived oxylipins.

Abstract: Disclosed are novel oxylipins, referred to herein as docosanoids, that are derived from C22 polyunsaturated fatty acids, and method of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6) as substrates for the production of novel oxylipins, and to the oxylipins produced thereby. Also disclosed is the use of DPAn-6, DPAn-3, DTAn-6, and/or the oxylipins derived therefrom, and/or novel docosanoids derived from the structures of C22 fatty acids, in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. The invention also relates to novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of LCPUFA-derived oxylipins, and particularly, docosanoids.

Abstract: The present invention is directed to a process for the preparation of the saponification products of lactones, preferably three- to eight-membered lactones. The present invention is also directed to a process for the preparation of compounds having general formula (I): wherein M is selected from the group consisting of cationic species, preferably metal cations (even more preferably Na), from a compound having the formula (II): comprising reacting a compound having formula (II) with a suitable hydroxide salt (M-OH) (III) such as, preferably, sodium hydroxide, in an aqueous medium. The reaction preferably utilizes a continuous process method for the substantial consumption of reagent and continuous, semi-continuous, and/or batch-wise processing for final consumption of reagent.

Abstract: This invention relates to an enzyme recovery sorbent, an enzyme recovery unit, a lignocellulosic biorefinery, a process for recycling enzymes, and a renewable material. The invention includes a lytic enzyme recovery sorbent suitable for use in production of renewable materials. The sorbent includes a substrate, and an enzyme binding material dispersed with respect to the substrate.

Abstract: Compositions and methods for controlling molluscs, members of the Gastropoda and Bivalvia classes which includes but is not limited to lactones, lactams, carbamates, amides, and/or carboxylic acid containing compounds as active ingredients and/or compounds derived from Pseudomonas and/or Erwinia. Also provided are methods and compositions for increasing the efficacy of chemical and biological control for invasive molluscs in open waters, power plants, and drinking water treatment facilities under coldwater conditions.

Abstract: A novel antimicrobial agent which has a high degree of safety, an excellent compounding property and strong antimicrobial activity is provided. The antimicrobial agent is characterized by containing ricinoleic acid monoglyceride or diglycerine ricinoleic acid monoester as an active ingredient. The antimicrobial agent of the present invention is suitable as a compounding component of an antimicrobial object selected from a food product, a food packaging material, tableware, a perfume cosmetic, a cosmetic, an external preparation for skin, a skin washing agent, a disinfectant, a lotion for external use, an agent for hair, a wiping sterilization agent, a pharmaceutical, a quasi drug and a hygiene material for the oral cavity.

Abstract: Disclosed is a process for purifying a hydroxycarboxylic acid, comprising: a crystallization step of subjecting a hydroxycarboxylic acid aqueous solution to crystallization for purification, a separation step of separating a hydroxycarboxylic acid crystal from a mother liquid, and a washing step of washing the hydroxycarboxylic acid crystal for further purification with a washing liquid, wherein the washing liquid is a hydroxycarboxylic acid aqueous solution. The purified or refined hydroxycarboxylic acid obtained through the above process is suitably used as a starting material for production of a polyhydroxycarboxylic acid. The above process is suitably included in a process for producing a cyclic ester and a process for producing a polyhydroxycarboxylic acid.

Abstract: The invention relates to acyl-carboxyphenylurea derivatives and to their physiologically tolerated salts and physiologically functional derivatives. Compounds of the formula I, in which the radicals have the stated meanings, and the physiological tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example for the treatment of type II diabetes.

Abstract: The invention relates to a process for converting ammonium salts of organic acids to the particular free organic acid, wherein an aqueous solution of the ammonium salt is contacted with an organic extractant and the salt is dissociated at temperatures and pressures at which the aqueous solution and the extractant are in the liquid state, and a stripping medium or entraining gas is introduced in order to remove NH3 from the aqueous solution and transfer at least a portion of the free organic acid formed to the organic extractant. The invention described here thus provides an improved process for releasing an organic acid, preferably a carboxylic, sulphonic or phosphonic acid, especially an alpha-hydroxycarboxylic acid or beta-hydroxycarboxylic acid, from the ammonium salt thereof by release and removal of ammonia and simultaneous extraction of the acid released with a suitable extractant from the aqueous phase. This process corresponds to a reactive extraction.

Abstract: One aspect of the present invention relates to a method for the kinetic resolution of racemic and diastereomeric mixtures of chiral compounds. The critical elements of the method are: a non-racemic chiral tertiary-amine-containing catalyst; a racemic or diastereomeric mixture of a chiral substrate, e.g., a cyclic carbonate or cyclic carbamate; and a nucleophile, e.g., an alcohol, amine or thiol. A preferred embodiment of the present invention relates to a method for achieving the kinetic resolution of racemic and diastereomeric mixtures of derivatives of ?- and ?-amino, hydroxy, and thio carboxylic acids. In certain embodiments, the methods of the present invention achieve dynamic kinetic resolution of a racemic or diastereomeric mixture of a substrate, i.e.

Abstract: The present invention provides a novel compound and antidepressant composition that can be effectively used for improving depressed mood and depressed state, particularly for depressed mood and depressed state in menopausal women. The compound of the present invention is represented by the following formula (1): wherein R1 and R2 are identical or different and represent a hydrogen atom, a hydroxyl group or an acetyloxy group, and n is an integer of 2 to 7, or a pharmaceutically acceptable salt or ester thereof. This compound is used as an active ingredient in the antidepressant composition. Examples of the compound of the invention include (2E)-9,10-dihydroxy-2-decenoic acid, (2Z)-9,10-dihydroxy-2-decenoic acid, (2E)-9-hydroxy-2-decenoic acid, and (2E)-7-acetoxy-2-heptenoic acid.

Abstract: The present invention is a mitochondria-targeted antioxidant prodrug useful for the prevention or treatment of diseases or conditions associated with mitochondrial dysfunction resulting from changes in the mitochondrial redox environment. Antioxidant prodrugs of the invention are produced by modifying an antioxidant to a fatty acid so that the resulting prodrug is targeted to and activated by an enzyme of mitochondrial fatty acid beta-oxidation.

Abstract: Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with various diseases, including ischemia.

Abstract: The present invention relates to an improved process for the preparation of lactic acid and or lactate from a magnesium lactate comprising medium. In said process, magnesium lactate is reacted with a hydroxide of sodium, calcium, and/or ammonium at a pH range between 9 and 12, preferably between 9.9 and 11, to form a lactate of sodium, potassium, calcium and/or ammonia and magnesium hydroxide. With the process according to the invention a lactate salt is formed and magnesium hydroxide. It is essential that said so-called SWAP reaction is conducted within a specific pH range: It was found that when conducting the SWAP reaction at a pH range between 9 and 12 magnesium hydroxide particles are formed which can easily be separated from the lactate salt solution formed.

Abstract: This invention relates to the use of hydroxybutyrate and poly hydroxybutyrate as components of animal feed or feed additives, as well as to compositions, feed additives and feed containing them. The inventors surprisingly found that hydroxybutyrate and poly-hydroxybutyrate, preferably 3-hydroxybutyrate and poly-3-hydroxybutyrate, have a great potential for use in animal feed for modulation of the gut flora. More precisely, it has been found that poly-3-hydroxybutyrate or a microbial strain capable for producing poly-3-hydroxybutyrate can be used as a potential growth promoter or gut flora modulator by releasing SCFA, preferably 3-hydroxy butyric acid, in the gut micro flora. Further, the inventors found that 3-hydroxybutyrate and poly-3-hydroxybutyrate have a great potential for suppressing or inhibiting pathogenic bacteria in the gastro intestinal tract, e.g. have a antimicrobial activity against strains of Vibrio, E. coli and Salmonella.

Abstract: A controlled nitric acid process employing oxygen and nitric acid as co-oxidants is used to oxidize organic compounds subject to nitric acid oxidation, to their corresponding carboxylic acids. Oxidation of some carbohydrates by this process can produce one or more of their corresponding acid forms. The process is carried out at moderate temperatures, typically in the range of 20° C. to 45° C. in a closed reactor, with oxygen gas being introduced into the reaction chamber as needed in order to sustain the reaction. Computer controlled reactors allow for careful and reproducible control of reaction parameters. Nitric acid can be recovered by a distillation/evaporation process, or by diffusion dialysis, the aqueous solution made basic with inorganic hydroxide, and the residual inorganic nitrate removed using a filtration (nanofiltration) device.

Abstract: The present invention relates to a process for producing an ether carboxylate which includes the steps of (1) reacting an aliphatic monohydric alcohol with an alkylene oxide in the presence of an alkali catalyst; (2) neutralizing a reaction solution obtained in the step (1) with an acid such as hydroxycarboxylic acids to obtain an ether alcohol; and (3-1) reacting the obtained ether alcohol with a monohalogenofatty acid or a salt thereof and an alkali metal hydroxide, or (3-2) subjecting the obtained ether alcohol to catalytic oxidation reaction in the presence of a catalyst. The obtained ether carboxylate has a less odor and a high quality and is therefore suitably used in the applications such as cosmetics and toiletries.

Abstract: An antiallergenic composition comprising 3-hydroxybutyric acid and/or a salt thereof. The antiallergenic composition is safe.

Abstract: Glycolic acid having a high purity is obtained by subjecting glycolic acid or a glycolic acid solution containing contaminants to double-chamber electrodialysis combined with one or more treatments selected from among treatment with an activated carbon, treatment with an ion exchange resin, concentration treatment and cooling crystallization.

Abstract: Processes are described for the production of an isolated medicinal composition for administration to mammals which comprises an effective amount of a free acid, salt or chelate of at least one naturally occurring form of an alpha hydroxyl organic acid comprising combining at least one naturally occurring form of an alpha hydroxy organic acid with an amount of base in an aqueous solution, wherein a total content of alpha hydroxyl organic acids amounts to between about 0.5% and about 35% w/w of the solution, for a time to hydrolyse substantially all forms of alpha hydroxyl organic acids present, neutralizing the solution to a pH between about 6.9 and about 7.6 to yield a free acid, salt or chelate of free acids of substantially all naturally occurring forms of alpha hydroxyl organic acids, and optionally lyophilizing the solution to produce an isolated medicinal composition. Compositions produced by these processes are disclosed and claimed.

Abstract: The invention is directed to methods of making organic compounds by metathesis and hydrocyanation. The method of the invention may be used, for example, to make industrial important organic compounds such as diacids, diesters, acid-amines, acid-alcohols, acid-nitriles, ester-amines, ester-alcohols, and ester-nitriles.

Abstract: The present invention relates to a compound represented by formula (I) wherein R1 represents optionally protected hydroxy or oxo, indicates ?-configuration, ?-configuration or a mixture of these in an arbitrary proportion, n represents an integer of 1 to 3, and m represents 0 or an integer of 1 to 10; and wherein two or more R1's are not bound to the same carbon atom other than the terminal carbon atom, a salt thereof or a prodrug thereof. The compounds represented by formula (I) have an ability to improve astrocyte function, and they are useful as a preventive and/or therapeutic agent for a brain infarction, neuronal dysfunction by brain infarction, Parkinson's disease, Parkinson's syndrome, amyotrophic lateral sclerosis or Alzheimer's disease.

Abstract: The invention provides a fluoroethercarboxylic acid which is represented by the general formula (I): Rf1OCHFCF2ORf2COOM ??(I) wherein Rf1 represents a partially or fully fluorinated alkyl group, which may optionally be interrupted with one or more oxygen atoms, Rf2 represents a partially or fully fluorinated alkylene group, which may optionally be interrupted with one or more oxygen atoms, and M represents a monovalent alkali metal, NH4 or H. The fluoroethercarboxylic acid can be suitably used as a surfactant and is low in bioaccumulation. The invention is also a method of fluoropolymer production and an aqueous fluoropolymer dispersion, using the fluoroethercarboxylic acid as a surfactant.

Abstract: ?-Ketol unsaturated fatty acid derivatives represented by the general formula (1); and plant growth regulators containing the same, which develop plant growth regulation performance such as flower bud formation acceleration in low concentrations and are excellent in stability: wherein R1 is straight-chain C1-5 alkyl or a straight-chain unsaturated C3-5 hydrocarbon group having one or two double bonds; and R2 is straight-chain C1-15 alkylene or a straight-chain unsaturated C2-15 hydrocarbon chain having one to three double bonds, with the proviso that the number of carbon-carbon double bonds is at most four.

Abstract: Integrated processes of preparing industrial chemicals starting from seed oil feedstock compositions containing one or more unsaturated fatty acids or unsaturated fatty acid esters, which are essentially free of metathesis catalyst poisons, particularly hydroperoxides; metathesis of the feedstock composition with a lower olefin, such as ethylene, to form a reduced chain olefin, preferably, a reduced chain ?-olefin, and a reduced chain unsaturated acid or ester, preferably, a reduced chain ?,?-unsaturated acid or ester. The reduced chain unsaturated acid or ester may be (trans)esterified to form a polyester polyolefin, which may be epoxidized to form a polyester polyepoxide. The reduced chain unsaturated acid or ester may be hydroformylated with reduction to produce an ?,?-hydroxy acid or ?,?-hydroxy ester, which may be (trans)esterified with a polyol to form an ?,?polyester polyol.

Abstract: Provided is a production method of glycolic acid having a first step of preparing glycolonitrile from formaldehyde and hydrocyanic acid and a second step of hydrolyzing the glycolonitrile into glycolic acid directly or via a glycolate salt, which method can produce glycolic acid in easy production and purification steps while consuming less energy. In the production method, by carrying out the first and second steps continuously or by storing the glycolonitrile obtained in the first step at pH 4 or less and carrying out a hydrolysis reaction of the second step at from pH 5 to 9, a production yield of glycolic acid, activity for the production of glycolic acid and accumulated concentration of glycolic acid are improved, resulting in the production of glycolic acid having an improved purity and quality.

Abstract: Alkoxy[13C]methyl phenyl sulfone is a precursor to the production of Lithium (E)-?-Alkoxy[1,2,3-13C3]acrylate and thence Alkoxy (E)-?-Alkoxy[1,2,3-13C3]acrylate. Alkoxy (E)-?-Alkoxy[1,2,3-13C3]acrylate can then serve as a precursor for the production of a number of other isotopically labeled compounds. Similar chemistry using Alkoxy[14C]methyl phenyl sulfone as the precursor can yield 14C labeled compounds. High purity precursors ensure that the new compounds are also highly pure.

Abstract: The present invention relates to dispersants for dispersing a particulate solid for millbases, paints and inks. The present invention provides a composition containing a particulate solid, a polar organic medium and a compound or salts thereof for formula T-(A)m(B)n—X-Z-Q(0-p) wherein T is hydrogen or a polymerisation terminating group; A is the residue of a hydroxy carboxylic acid or lactone thereof; B is the residue of an amino carboxylic acid; X is a direct bond or a divalent group; Z is an acidic or basic group or a moiety which contains an acidic or basic group; Q is an optional residue of an oxide, urea or a dibasic acid or anhydride thereof; m and n are positive integers; and p represents the number of residual amino and/or imino groups in Z.

Abstract: Processes for producing a hydroxyalkyl(meth)acrylate which comprise reacting (meth)acrylic acid with an alkylene oxide in the presence of a catalyst. A first process is characterized in that the amount of the acid ingredient is kept, on calculation, at 0.010 or more in terms of molar ratio to the catalyst present in the liquid reaction mixture and that the liquid reaction mixture from which the hydroxyalkyl(meth)acrylate has been distilled off is used in the subsequent reaction. A second process is characterized in that a dialkylene glycol mono(meth)acylate is supplied to the reaction system to cause the dialkyleneglycol mono(meth)acylate to coexist in the liquid reaction mixture.

Abstract: A dispersant comprising a polyester chain obtainable by polymerising a hydroxy carboxylic acid or lactone thereof such as ?-caprolactone with a cyclic alkylene carbonate such as 5,5-dimethyltrimethylene carbonate. The dispersant may be in the form of a phosphate ester where the polyester chain is reacted with a phosphating agent such as polyphosphoric acid or the polyester chain may be attached to a polyamine or polyimine such as polyethyleneimine.

Abstract: The compounds of the general formula (I) in which X is represents two hydrogen atoms, a ?-bond, oxygen or methylene: R2 is a C6-C12 aryl, or arylalkyl residue: R3 is hydrogen, 2-hydroxyethyl or 2-aminoethyl are useful for the treatment of pathologies mediated by vanilloid receptors type I.

Abstract: A carbon nanotube dispersion includes a carbon nanotube compound represented by structural formula A and a dispersion medium in which the carbon nanotube is dispersed or dissolved, wherein a moiety represented by double lines represents a carbon nanotube R1 represents a hydrogen atom, a substituted or unsubstituted alkyl group having one or two carbon atoms, a substituted or unsubstituted aryl group or a substituted or unsubstituted carbodiimide group, R2 represents a substituted or unsubstituted alkyl group having from 1 to 4 carbon atoms, and m and n each independently represents an integer of 1 or more.